Download PDF
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2022; 82(10): 1044-1054
DOI: 10.1055/a-1904-6100
GebFra Science
Review/Übersicht

Fortgeschrittenes Mammakarzinom

ABC6-Konsens im Fokus der AGO-Empfehlungen 2022 Article in several languages: English | deutsch
Michael Untch
1   Klinik für Gynäkologie und Geburtshilfe, Multidisziplinäres Brustzentrum und Zentrum für gynäkologische Onkologie, HELIOS Klinikum Berlin Buch, Berlin, Germany
,
Peter A. Fasching
2   Universitätsfrauenklinik Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
,
Renate Haidinger
3   Brustkrebs Deutschland e. V., Hohenbrunn, Germany; Patientenvertreterin, ABC6-Ko-Vorsitz, ABC-Panelistin
,
Nadia Harbeck
4   Brustzentrum, Klinik und Poliklinik für Frauenheilkunde und Comprehensive Cancer Center (CCC) München, LMU Klinikum, München, Germany; ABC-Panelistin
,
Christian Jackisch
5   Klinik für Gynäkologie und Geburtshilfe, Sana Klinikum Offenbach GmbH, Offenbach, Germany
,
Diana Lüftner
6   Immanuel Klinik Märkische Schweiz, Medizinische Hochschule Brandenburg Theodor-Fontane, Buckow, Germany
,
Volkmar Müller
7   Universitätsklinik für Gynäkologie, Hamburg-Eppendorf, Hamburg, Germany
,
Eva Schumacher-Wulf
8   Mamma Mia! Brustkrebsmagazin, Köln, Germany; Patientenvertreterin
,
Rachel Würstlein
9   Brustzentrum, Klinik und Poliklinik für Frauenheilkunde und Comprehensive Cancer Center (CCC) München, LMU Klinikum, München, Germany
,
Christoph Thomssen
10   Universitätsfrauenklinik, Martin-Luther-Universität, Halle an der Saale, Germany; ABC-Panelist
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

In der Behandlung des fortgeschrittenen Mammakarzinoms gab es in den letzten Jahren zahlreiche Fortschritte, die in internationale und nationale Therapieempfehlungen eingeflossen sind und dazu beigetragen haben, die Prognose der Patient*innen zu verbessern. Im November 2021 tagte die 6. „Internationale Konsensuskonferenz zum fortgeschrittenen Mammakarzinom“ (ABC6: 6th International Consensus Conference for Advanced Breast Cancer). Ziel ist es, die Behandlung des fortgeschrittenen Mammakarzinoms weltweit auf hohem Evidenzlevel zu standardisieren und neue Therapieoptionen allen Patient*innen zugänglich zu machen. Im vorliegenden Manuskript geht es darum, den ABC6-Konsensus vor dem Hintergrund der deutschen Therapieempfehlungen zu diskutieren und mit dem klinischen Vorgehen in Deutschland abzugleichen. Die Autoren beziehen sich auf die aktuellen Empfehlungen der Arbeitsgemeinschaft gynäkologische Onkologie, Kommission Mamma (AGO Mamma) vom März 2022. Die Empfehlungen der AGO Mamma werden jährlich aktualisiert. Ein solcher Abgleich erscheint sinnvoll, da aufgrund länderspezifischer Besonderheiten Abweichungen zwischen internationalen und nationalen Empfehlungen bestehen können. Die deutschen Autoren beziehen sich auf die Abstimmungsergebnisse der ABC6-Panelisten vom 06. November 2021.

Schlüsselwörter

fortgeschrittenes Mammakarzinom - Systemtherapie - Therapiesequenz - Oligometastasierung - Hirnmetastasen - Supportivbehandlung


Publication History

Received: 15 May 2022

Accepted: 18 July 2022

Article published online:
30 September 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 AGO Kommission Mamma. Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome (März 2022). Accessed April 01, 2022 at: https://www.ago-online.de/leitlinien-empfehlungen/leitlinien-empfehlungen/kommission-mamma
    PubMed
  • 2 Thill M, Lüftner D, Kolberg-Liedtke C. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. Breast Care (Basel) 2022;
    CrossrefPubMedSearch in Google Scholar
  • 3 Dykewicz CA. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis 2001; 33: 139-144
    CrossrefPubMedSearch in Google Scholar
  • 4 Bruckmann NM, Kirchner J, Umutlu L. et al. Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. Eur Radiol 2021; 31: 8714-8724
    CrossrefPubMedSearch in Google Scholar
  • 5 Morawitz J, Bruckmann N-M, Dietzel F. et al. Comparison of nodal staging between CT, MRI, and 18F‑FDG PET/MRI in patients with newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging 2021;
    CrossrefPubMedSearch in Google Scholar
  • 6 Schmid P. KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC (16.07.2021). Accessed April 22, 2022 at: https://www.esmo.org/meetings/keynote-522-phase-iii-study-of-neoadjuvant-chemotherapy-vs-placebo-chemotherapy-followed-by-adjuvant-vs-placebo-for-early-stage-tnbc?hit=ehp
    PubMed
  • 7 Schneeweiss A, Chia S, Hickish T. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24: 2278-2284
    CrossrefPubMedSearch in Google Scholar
  • 8 Tutt A, Garber JE, Kaufman B. et al. OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. J Clin Oncol 2021; 39: LBA1
    CrossrefPubMedSearch in Google Scholar
  • 9 Soran A, Ozmen V, Ozbas S. et al. Primary Surgery with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-year Follow-up; Protocol MF07-01 Randomized Clinical Trial. J Am Coll Surg 2021; 233: 742-751.e5
    CrossrefPubMedSearch in Google Scholar
  • 10 Palma DA, Olson R, Harrow S. et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol 2020; 38: 2830-2838
    CrossrefPubMedSearch in Google Scholar
  • 11 Nash AL, Thomas SM, Plichta JK. et al. Contralateral Axillary Nodal Metastases: Stage IV Disease or a Manifestation of Progressive Locally Advanced Breast Cancer?. Ann Surg Oncol 2021; 28: 5544-5552
    CrossrefPubMedSearch in Google Scholar
  • 12 Foley NM, Coll JM, Lowery AJ. et al. Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ER-/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact?. Pathol Oncol Res 2018; 24: 881-884
    CrossrefPubMedSearch in Google Scholar
  • 13 Park YH, Kim T-Y, Kim GM. et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2019; 20: 1750-1759
    CrossrefPubMedSearch in Google Scholar
  • 14 Martin M, Zielinski C, Ruiz-Borrego M. et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. Ann Oncol 2021; 32: 488-499
    CrossrefPubMedSearch in Google Scholar
  • 15 André F, Ciruelos EM, Juric D. et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 2021; 32: 208-217
    CrossrefPubMedSearch in Google Scholar
  • 16 Rugo HS, Lerebours F, Ciruelos E. et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 2021; 22: 489-498
    CrossrefPubMedSearch in Google Scholar
  • 17 DeMichele A, Clark AS, Tan KS. et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res 2015; 21: 995-1001
    CrossrefPubMedSearch in Google Scholar
  • 18 Cortés J, Kim SB, Chung WP. et al. DESTINY-Breast03 Trial Investigators. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med 2022; 386: 1143-1154
    CrossrefPubMedSearch in Google Scholar
  • 19 Murthy RK, Loi S, Okines A. et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 2020; 382: 597-609
    CrossrefPubMedSearch in Google Scholar
  • 20 Gennari A, André F, Barrios CH. et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 2021;
    CrossrefPubMedSearch in Google Scholar
  • 21 Modi S, Saura C, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020; 382: 610-621
    CrossrefPubMedSearch in Google Scholar
  • 22 Bardia A, Hurvitz SA, Tolaney SM. et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 2021; 384: 1529-1541
    CrossrefPubMedSearch in Google Scholar
  • 23 Tung NM, Robson ME, Ventz S. et al. TBCRC048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol 2020; 38: 4274-4282
    CrossrefPubMedSearch in Google Scholar
  • 24 Robson ME, Tung N, Conte P. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physicianʼs choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019; 30: 558-566
    CrossrefPubMedSearch in Google Scholar
  • 25 Litton JK, Hurvitz SA, Mina LA. et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 2020; 31: 1526-1535
    CrossrefPubMedSearch in Google Scholar
  • 26 Schmid P, Adams S, Rugo HS. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018; 379: 2108-2121
    CrossrefPubMedSearch in Google Scholar
  • 27 Cortes J, Cescon DW, Rugo HS. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020; 396: 1817-1828
    CrossrefPubMedSearch in Google Scholar
  • 28 von Minckwitz G, Huang C-S, Mano MS. et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019; 380: 617-628
    CrossrefPubMedSearch in Google Scholar
  • 29 Montemurro F, Delaloge S, Barrios CH. et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase III b clinical trial☆. Ann Oncol 2020; 31: 1350-1358
    CrossrefPubMedSearch in Google Scholar
  • 30 Deutsche Gesellschaft für Palliativmedizin. S3-Leitlinie Palliativmedizin. Accessed November 19, 2021 at: https://www.dgpalliativmedizin.de/images/stories/pdf/LL_Palliativmedizin_Langversion_2.2.pdf
    PubMed
  • 31 Deutsche Gesellschaft für Supportivmedizin. S3-Leitlinie Supportiv Therapie bei onkologischen Patienten – AWMF. Accessed November 19, 2021 at: https://www.awmf.org/uploads/tx_szleitlinien/032-054OLl_S3_Supportiv_2020-07.pdf
    PubMed
  • 32 Loeser AL, Peppercorn JM, Burkard ME. et al. Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC). J Clin Oncol 2021; 39: 1005
    CrossrefPubMedSearch in Google Scholar